Study: Natural Immunity as Good as or Better Than COVID-19 Vaccination; A Biotech Company that Once Claimed to have a ‘cure’ for COVID-19 Just Filed for Bankruptcy, Sending Shares Plunging 61%, and other C-Virus related stories
Natural Immunity as Good as or Better Than COVID-19 Vaccination: Study:
Post-infection immunity is similar or even superior to the protection bestowed by COVID-19 vaccines, according to a new study.
Post-infection protection—known widely as natural immunity—was strong and remained significant over time, researchers found. Against the Wuhan, Alpha, and Delta variants, the protection against re-infection was 85 percent at four weeks, 78 percent at 40 weeks, and 55.5 percent at 80 weeks.
That protection dropped more quickly against the Omicron BA.1 subvariant, declining to 36 percent by 40 weeks, and protection against symptomatic disease also waned below 50 percent.
But shielding against severe disease was strong against all strains, including the BA.1 subvariant, researchers found. The naturally immune enjoyed 88.9 percent protection against BA.1 at 40 weeks, which was actually higher than against earlier strains.
“Our analysis found significantly reduced protection against re-infection from the omicron BA.1 variant but that levels of protection against severe disease remained high,” Dr. Stephen Lim of the Institute for Health Metrics and Evaluation at the University of Washington’s School of Medicine, and his co-authors, said in the study.
Dr. Brett Giroir, a former Trump administration health official whose post on natural immunity was censored by Twitter on behalf of Pfizer board member Dr. Scott Gottlieb, said the study “demonstrates robustness of natural immunity.”
Dr. Vinay Prasad, an epidemiologist at the University of California, San Francisco who was also not involved in the study, said that the paper made a “compelling case that we can effectively stop boosting average risk individuals (most adults) who have had covid.” —>READ MORE HERE
A biotech company that once claimed to have a ‘cure’ for COVID-19 just filed for bankruptcy, sending shares plunging 61%:
Sorrento Therapeutics a biotech company working on a COVID-19 therapy and once targeted by short-seller Hindenburg Research, plunged as much as 61% after the firm filed for Chapter 11 bankruptcy protection on Monday.
Shares of the company traded around 39 cents at 1:15 p.m. ET.
Sorrento made headlines in May of 2020 when founder Dr. Henry Ji claimed that the company discovered a cure to COVID-19, which caused its stock to soar 243% in a single day. This took the company’s market cap from millions to well over a billion.
“We want to emphasize there is a cure. There is a solution that works 100 percent,” Ji told Fox News, a statement that was refuted by health care experts. “If we have the neutralizing antibody in your body, you don’t need the social distancing. You can open up a society without fear.”
Hindenburg released a scathing report on the biotech firm following Ji’s comments, which caused Sorrento’s stock to drastically decline in value. —>READ MORE HERE
Follow links below to relevant/related stories and resources:
Kristi Noem compares other states’ COVID-19 response to Chinese Communist Party
Mayor Eric Adams lets fired anti-vax workers re-apply — but with no back pay or job guarantee
USA TODAY: Coronavirus Updates
YAHOO NEWS: Coronavirus Live Updates
NEW YORK POST: Coronavirus The Latest
If you like what you see, please “Like” and/or Follow us on FACEBOOK here, GETTR here, and TWITTER here.
Comments are closed.